Soo Chin Lee

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells

Majid Ebrahimi Warkiani, Guofeng Guan, Khoo Bee Luan et al. · Lab on a Chip · 2013 · 573 citations · Full text

IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer

L.S. Ong, Wee Chyan Lee, Shijun Ma et al. · Proceedings of the National Academy of Sciences · 2022 · 565 citations · Full text

The genomic landscape of nasopharyngeal carcinoma

De‐Chen Lin, Xuan Meng, Masaharu Hazawa et al. · Nature Genetics · 2014 · 370 citations

Tumor Heterogeneity, Genomic Landscape, Nasopharyngeal Cancer +5

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

Ahmad Awada, Rámón Colomer, Kenichi Inoue et al. · JAMA Oncology · 2016 · 310 citations · Full text